Abstract
Summary
The global Enbrel (Etanercept) Biosimilar market size is projected to grow from US$ 1219.9 million in 2022 to US$ 1688.2 million in 2029; it is expected to grow at a CAGR of 4.8% from 2023 to 2029.
United States market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Enbrel (Etanercept) Biosimilar players cover Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
LPI (LP Information)' newest research report, the “Enbrel (Etanercept) Biosimilar Industry Forecast” looks at past sales and reviews total world Enbrel (Etanercept) Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Enbrel (Etanercept) Biosimilar sales for 2023 through 2029. With Enbrel (Etanercept) Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Enbrel (Etanercept) Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Enbrel (Etanercept) Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Enbrel (Etanercept) Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Enbrel (Etanercept) Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Enbrel (Etanercept) Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Enbrel (Etanercept) Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Enbrel (Etanercept) Biosimilar market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Syringe
Pen
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Samsung Bioepis
Novartis
3s Bio
Lupin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Enbrel (Etanercept) Biosimilar market?
What factors are driving Enbrel (Etanercept) Biosimilar market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Enbrel (Etanercept) Biosimilar market opportunities vary by end market size?
How does Enbrel (Etanercept) Biosimilar break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Enbrel (Etanercept) Biosimilar players cover Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
LPI (LP Information)' newest research report, the “Enbrel (Etanercept) Biosimilar Industry Forecast” looks at past sales and reviews total world Enbrel (Etanercept) Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Enbrel (Etanercept) Biosimilar sales for 2023 through 2029. With Enbrel (Etanercept) Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Enbrel (Etanercept) Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Enbrel (Etanercept) Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Enbrel (Etanercept) Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Enbrel (Etanercept) Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Enbrel (Etanercept) Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Enbrel (Etanercept) Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Enbrel (Etanercept) Biosimilar market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Syringe
Pen
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Samsung Bioepis
Novartis
3s Bio
Lupin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Enbrel (Etanercept) Biosimilar market?
What factors are driving Enbrel (Etanercept) Biosimilar market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Enbrel (Etanercept) Biosimilar market opportunities vary by end market size?
How does Enbrel (Etanercept) Biosimilar break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Enbrel (Etanercept) Biosimilar Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Enbrel (Etanercept) Biosimilar by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Enbrel (Etanercept) Biosimilar by Country/Region, 2018, 2022 & 2029
2.2 Enbrel (Etanercept) Biosimilar Segment by Type
2.2.1 Syringe
2.2.2 Pen
2.3 Enbrel (Etanercept) Biosimilar Sales by Type
2.3.1 Global Enbrel (Etanercept) Biosimilar Sales Market Share by Type (2018-2023)
2.3.2 Global Enbrel (Etanercept) Biosimilar Revenue and Market Share by Type (2018-2023)
2.3.3 Global Enbrel (Etanercept) Biosimilar Sale Price by Type (2018-2023)
2.4 Enbrel (Etanercept) Biosimilar Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Enbrel (Etanercept) Biosimilar Sales by Application
2.5.1 Global Enbrel (Etanercept) Biosimilar Sale Market Share by Application (2018-2023)
2.5.2 Global Enbrel (Etanercept) Biosimilar Revenue and Market Share by Application (2018-2023)
2.5.3 Global Enbrel (Etanercept) Biosimilar Sale Price by Application (2018-2023)
3 Global Enbrel (Etanercept) Biosimilar by Company
3.1 Global Enbrel (Etanercept) Biosimilar Breakdown Data by Company
3.1.1 Global Enbrel (Etanercept) Biosimilar Annual Sales by Company (2018-2023)
3.1.2 Global Enbrel (Etanercept) Biosimilar Sales Market Share by Company (2018-2023)
3.2 Global Enbrel (Etanercept) Biosimilar Annual Revenue by Company (2018-2023)
3.2.1 Global Enbrel (Etanercept) Biosimilar Revenue by Company (2018-2023)
3.2.2 Global Enbrel (Etanercept) Biosimilar Revenue Market Share by Company (2018-2023)
3.3 Global Enbrel (Etanercept) Biosimilar Sale Price by Company
3.4 Key Manufacturers Enbrel (Etanercept) Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Enbrel (Etanercept) Biosimilar Product Location Distribution
3.4.2 Players Enbrel (Etanercept) Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Enbrel (Etanercept) Biosimilar by Geographic Region
4.1 World Historic Enbrel (Etanercept) Biosimilar Market Size by Geographic Region (2018-2023)
4.1.1 Global Enbrel (Etanercept) Biosimilar Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Enbrel (Etanercept) Biosimilar Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Enbrel (Etanercept) Biosimilar Market Size by Country/Region (2018-2023)
4.2.1 Global Enbrel (Etanercept) Biosimilar Annual Sales by Country/Region (2018-2023)
4.2.2 Global Enbrel (Etanercept) Biosimilar Annual Revenue by Country/Region (2018-2023)
4.3 Americas Enbrel (Etanercept) Biosimilar Sales Growth
4.4 APAC Enbrel (Etanercept) Biosimilar Sales Growth
4.5 Europe Enbrel (Etanercept) Biosimilar Sales Growth
4.6 Middle East & Africa Enbrel (Etanercept) Biosimilar Sales Growth
5 Americas
5.1 Americas Enbrel (Etanercept) Biosimilar Sales by Country
5.1.1 Americas Enbrel (Etanercept) Biosimilar Sales by Country (2018-2023)
5.1.2 Americas Enbrel (Etanercept) Biosimilar Revenue by Country (2018-2023)
5.2 Americas Enbrel (Etanercept) Biosimilar Sales by Type
5.3 Americas Enbrel (Etanercept) Biosimilar Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Enbrel (Etanercept) Biosimilar Sales by Region
6.1.1 APAC Enbrel (Etanercept) Biosimilar Sales by Region (2018-2023)
6.1.2 APAC Enbrel (Etanercept) Biosimilar Revenue by Region (2018-2023)
6.2 APAC Enbrel (Etanercept) Biosimilar Sales by Type
6.3 APAC Enbrel (Etanercept) Biosimilar Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Enbrel (Etanercept) Biosimilar by Country
7.1.1 Europe Enbrel (Etanercept) Biosimilar Sales by Country (2018-2023)
7.1.2 Europe Enbrel (Etanercept) Biosimilar Revenue by Country (2018-2023)
7.2 Europe Enbrel (Etanercept) Biosimilar Sales by Type
7.3 Europe Enbrel (Etanercept) Biosimilar Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Enbrel (Etanercept) Biosimilar by Country
8.1.1 Middle East & Africa Enbrel (Etanercept) Biosimilar Sales by Country (2018-2023)
8.1.2 Middle East & Africa Enbrel (Etanercept) Biosimilar Revenue by Country (2018-2023)
8.2 Middle East & Africa Enbrel (Etanercept) Biosimilar Sales by Type
8.3 Middle East & Africa Enbrel (Etanercept) Biosimilar Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Enbrel (Etanercept) Biosimilar
10.3 Manufacturing Process Analysis of Enbrel (Etanercept) Biosimilar
10.4 Industry Chain Structure of Enbrel (Etanercept) Biosimilar
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Enbrel (Etanercept) Biosimilar Distributors
11.3 Enbrel (Etanercept) Biosimilar Customer
12 World Forecast Review for Enbrel (Etanercept) Biosimilar by Geographic Region
12.1 Global Enbrel (Etanercept) Biosimilar Market Size Forecast by Region
12.1.1 Global Enbrel (Etanercept) Biosimilar Forecast by Region (2024-2029)
12.1.2 Global Enbrel (Etanercept) Biosimilar Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Enbrel (Etanercept) Biosimilar Forecast by Type
12.7 Global Enbrel (Etanercept) Biosimilar Forecast by Application
13 Key Players Analysis
13.1 Samsung Bioepis
13.1.1 Samsung Bioepis Company Information
13.1.2 Samsung Bioepis Enbrel (Etanercept) Biosimilar Product Portfolios and Specifications
13.1.3 Samsung Bioepis Enbrel (Etanercept) Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Samsung Bioepis Main Business Overview
13.1.5 Samsung Bioepis Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Enbrel (Etanercept) Biosimilar Product Portfolios and Specifications
13.2.3 Novartis Enbrel (Etanercept) Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 3s Bio
13.3.1 3s Bio Company Information
13.3.2 3s Bio Enbrel (Etanercept) Biosimilar Product Portfolios and Specifications
13.3.3 3s Bio Enbrel (Etanercept) Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 3s Bio Main Business Overview
13.3.5 3s Bio Latest Developments
13.4 Lupin
13.4.1 Lupin Company Information
13.4.2 Lupin Enbrel (Etanercept) Biosimilar Product Portfolios and Specifications
13.4.3 Lupin Enbrel (Etanercept) Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Lupin Main Business Overview
13.4.5 Lupin Latest Developments
14 Research Findings and Conclusion